Dupilumab: A Review of Present Indications and Off-Label Uses

Dupilumab, a monoclonal antibody that inhibits IL-4 and IL-13 signaling, is being explored for a variety of new indications beyond its current uses. These include several skin diseases (e.g., prurigo nodularis, nummular eczema, allergic contact dermatitis, chronic hand eczema, spontaneous chronic urticaria, bullous pemphigoid, alopecia areata, and Netherton syndrome), respiratory diseases (e.g., allergic bronchopulmonary aspergillosis, chronic eosinophilic pneumonia, and allergic rhinitis), and eosinophilic gastrointestinal disorders (e.g., eosinophilic esophagitis) and food allergies. The review discusses published data and ongoing clinical trials investigating dupilumab's efficacy in these conditions.